MGC Pharmaceuticals says study shows no effects on driving from epilepsy treatment

MGC Pharmaceuticals' Nadya Lisovoder joins Proactive London to talk about positive results from a recent study investigating the effects on vehicle driving performance, sedation and mood shortly after taking its epilepsy treatment CannEpil. The study showed CannEpil was safe for post-treatment driving after assessing 31 healthy, fully licensed drivers (15 male, 16 female) aged between 21 and 58 years with a median age of 36 years of age.

Category